[
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Tesla, Intel, Enphase, Bristol Myers, Boeing, AT&T, and More",
    "summary": "Tesla stock rises as CEO Elon Musk says in May he’ll be cutting back ’significantly’ his work with the Trump administration’s Department of Government Efficiency.",
    "url": "https://finnhub.io/api/news?id=80cc144952ed318694a8763374e28be392c807d71dd6ece91fdb603c1299945e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745439420,
      "headline": "These Stocks Moved the Most Today: Tesla, Intel, Enphase, Bristol Myers, Boeing, AT&T, and More",
      "id": 134059407,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Tesla stock rises as CEO Elon Musk says in May he’ll be cutting back ’significantly’ his work with the Trump administration’s Department of Government Efficiency.",
      "url": "https://finnhub.io/api/news?id=80cc144952ed318694a8763374e28be392c807d71dd6ece91fdb603c1299945e"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Tesla, Intel, Enphase, Bristol Myers, Boeing, AT&T, and More",
    "summary": "Tesla stock rises as CEO Elon Musk says in May he’ll be cutting back ’significantly’ his work with the Trump administration’s Department of Government Efficiency.",
    "url": "https://finnhub.io/api/news?id=65f0d46e40689744cf36274fabe79ee925113c8103779627990ec5ebe2fe208e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745433600,
      "headline": "These Stocks Are Moving the Most Today: Tesla, Intel, Enphase, Bristol Myers, Boeing, AT&T, and More",
      "id": 134046249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Tesla stock rises as CEO Elon Musk says in May he’ll be cutting back ’significantly’ his work with the Trump administration’s Department of Government Efficiency.",
      "url": "https://finnhub.io/api/news?id=65f0d46e40689744cf36274fabe79ee925113c8103779627990ec5ebe2fe208e"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More",
    "summary": "BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.",
    "url": "https://finnhub.io/api/news?id=ed17d9fbc90b17ac7c42a71a98898893d19a8bd9461d58dc89205cf60917efa8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745426220,
      "headline": "Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More",
      "id": 134046621,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.",
      "url": "https://finnhub.io/api/news?id=ed17d9fbc90b17ac7c42a71a98898893d19a8bd9461d58dc89205cf60917efa8"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook",
    "summary": "Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said in a statement.",
    "url": "https://finnhub.io/api/news?id=dc1f9ecce519c68167c3629889bf573cd31e89911e1b7d5fce5764c01313c951",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745418540,
      "headline": "Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook",
      "id": 134046622,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said in a statement.",
      "url": "https://finnhub.io/api/news?id=dc1f9ecce519c68167c3629889bf573cd31e89911e1b7d5fce5764c01313c951"
    }
  },
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Stock That Will Always Grow?",
    "summary": "We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming over […]",
    "url": "https://finnhub.io/api/news?id=239b699f27f69dc79067ef0504ccb0654f9ae0460f38b8cf449d4a4a6fa35427",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745418002,
      "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Stock That Will Always Grow?",
      "id": 134046623,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming over […]",
      "url": "https://finnhub.io/api/news?id=239b699f27f69dc79067ef0504ccb0654f9ae0460f38b8cf449d4a4a6fa35427"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides",
    "summary": "Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. In the Phase 3 trial, adjunctive Cobenfy treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo with an atypical antipsycho",
    "url": "https://finnhub.io/api/news?id=3c461fd13c9319e93134664853898eed202f8ec6872f2d5cfd37ecf52647f7fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745416533,
      "headline": "Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides",
      "id": 134046624,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. In the Phase 3 trial, adjunctive Cobenfy treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo with an atypical antipsycho",
      "url": "https://finnhub.io/api/news?id=3c461fd13c9319e93134664853898eed202f8ec6872f2d5cfd37ecf52647f7fc"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi",
    "summary": "Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=f56e02096ab4251282ea64e8c6c519803d79c57f643beda60c326085dcb2c7da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745414700,
      "headline": "The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi",
      "id": 134046316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=f56e02096ab4251282ea64e8c6c519803d79c57f643beda60c326085dcb2c7da"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect",
    "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know.",
    "url": "https://finnhub.io/api/news?id=d73bc4a6604ea99b1e3c69a45c992fb249e41ae70384d1f844d6b36f9a4e7491",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745409687,
      "headline": "Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect",
      "id": 134046626,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know.",
      "url": "https://finnhub.io/api/news?id=d73bc4a6604ea99b1e3c69a45c992fb249e41ae70384d1f844d6b36f9a4e7491"
    }
  },
  {
    "ts": null,
    "headline": "BMS’ schizophrenia therapy fails in Phase III trial as an adjunctive treatment",
    "summary": "The therapy showed a two-point reduction in total PANSS score at week six against placebo with atypical antipsychotic.",
    "url": "https://finnhub.io/api/news?id=068d34cad97c7b533f825e3386a90bc4db4de9d49e42f15a015bc5d26d1e1cb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745400122,
      "headline": "BMS’ schizophrenia therapy fails in Phase III trial as an adjunctive treatment",
      "id": 134046627,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The therapy showed a two-point reduction in total PANSS score at week six against placebo with atypical antipsychotic.",
      "url": "https://finnhub.io/api/news?id=068d34cad97c7b533f825e3386a90bc4db4de9d49e42f15a015bc5d26d1e1cb7"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers’ prized schizophrenia drug stumbles in testing",
    "summary": "A late-stage study found Cobenfy wasn’t better than a placebo as an add-on to atypical antipsychotics. Some analysts view the failure as a “significant hit” to the drug’s commercial outlook.",
    "url": "https://finnhub.io/api/news?id=07e58c2416e4eb63011f0fab97d42085eaafdd0ce45767d272e765c232bf29a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745396940,
      "headline": "Bristol Myers’ prized schizophrenia drug stumbles in testing",
      "id": 134046628,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "A late-stage study found Cobenfy wasn’t better than a placebo as an add-on to atypical antipsychotics. Some analysts view the failure as a “significant hit” to the drug’s commercial outlook.",
      "url": "https://finnhub.io/api/news?id=07e58c2416e4eb63011f0fab97d42085eaafdd0ce45767d272e765c232bf29a0"
    }
  },
  {
    "ts": null,
    "headline": "Piper Sandler Initiates Coverage of Bristol-Myers Squibb (BMY) with Overweight Recommendation",
    "summary": "Piper Sandler Initiates Coverage of Bristol-Myers Squibb (BMY) with Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=6c41c7efe1631d9af991be1c052704fc8ab0ecb588e2c5aa2917a556c5025fd6",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745366589,
      "headline": "Piper Sandler Initiates Coverage of Bristol-Myers Squibb (BMY) with Overweight Recommendation",
      "id": 134037583,
      "image": "",
      "related": "BMY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6c41c7efe1631d9af991be1c052704fc8ab0ecb588e2c5aa2917a556c5025fd6"
    }
  }
]